We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
Read MoreHide Full Article
Alkermes plc (ALKS - Free Report) announced that it has entered into a clinical trial collaboration and supply agreement with pharma giant, Merck (MRK - Free Report) , for a phase III study evaluating its investigational IL-2 variant immunotherapy, nemvaleukin alfa, in combination with the latter’s PD-L1 inhibitor, Keytruda (pembrolizumab), for treating patients with platinum-resistant ovarian cancer.
Per the agreement, Alkermes will conduct the phase III study which will evaluate the combo of nemvaleukin alfa plus Keytruda as compared to investigator-choice chemotherapy in the given patient population. The company plans to initiate the study in the second half of 2021.
Per the company, patients with platinum-resistant ovarian cancer have limited treatment options available and the overall survival remains low. Currently, there is no anti-PD-1 treatment approved for this indication. Hence, if successfully developed and upon potential approval, nemvaleukin alfa can lend a big boost to Alkermes’ growth prospect.
Shares of Alkermes have declined 4.4% so far this year compared with the industry’s decrease of 5.3%.
Notably, nemvaleukin alfa is being evaluated under Alkermes’ ARTISTRY clinical development program in patients with advanced solid tumors.
The phase I/II studies – ARTISTRY-1 and ARTISTRY-2, are evaluating the safety, tolerability, efficacy and pharmacokinetic and pharmacodynamic effects of nemvaleukin in patients with refractory advanced solid tumors, both as a monotherapy and in combination with Keytruda.
The ARTISTRY-1 study is evaluating intravenous administration of nemvaleukin, while in the ongoing phase II efficacy expansion stage of ARTISTRY-2 study, nemvaleukin is being administered subcutaneously.
Meanwhile, the phase II ARTISTRY-3 study is investigating the clinical and immunologic effects of intravenous nemvaleukin as a monotherapy in several advanced, malignant solid tumors.
Repligen’s earnings estimates have been revised 15.1% upward for 2021 and 9.8% upward for 2022 over the past 60 days. The stock has increased 5% year to date.
Nabriva’s loss per share estimates have narrowed 45.8% for 2021 and 50.9% for 2022 over the past 60 days.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
Alkermes plc (ALKS - Free Report) announced that it has entered into a clinical trial collaboration and supply agreement with pharma giant, Merck (MRK - Free Report) , for a phase III study evaluating its investigational IL-2 variant immunotherapy, nemvaleukin alfa, in combination with the latter’s PD-L1 inhibitor, Keytruda (pembrolizumab), for treating patients with platinum-resistant ovarian cancer.
Per the agreement, Alkermes will conduct the phase III study which will evaluate the combo of nemvaleukin alfa plus Keytruda as compared to investigator-choice chemotherapy in the given patient population. The company plans to initiate the study in the second half of 2021.
Per the company, patients with platinum-resistant ovarian cancer have limited treatment options available and the overall survival remains low. Currently, there is no anti-PD-1 treatment approved for this indication. Hence, if successfully developed and upon potential approval, nemvaleukin alfa can lend a big boost to Alkermes’ growth prospect.
Shares of Alkermes have declined 4.4% so far this year compared with the industry’s decrease of 5.3%.
Notably, nemvaleukin alfa is being evaluated under Alkermes’ ARTISTRY clinical development program in patients with advanced solid tumors.
The phase I/II studies – ARTISTRY-1 and ARTISTRY-2, are evaluating the safety, tolerability, efficacy and pharmacokinetic and pharmacodynamic effects of nemvaleukin in patients with refractory advanced solid tumors, both as a monotherapy and in combination with Keytruda.
The ARTISTRY-1 study is evaluating intravenous administration of nemvaleukin, while in the ongoing phase II efficacy expansion stage of ARTISTRY-2 study, nemvaleukin is being administered subcutaneously.
Meanwhile, the phase II ARTISTRY-3 study is investigating the clinical and immunologic effects of intravenous nemvaleukin as a monotherapy in several advanced, malignant solid tumors.
Zacks Rank & Stocks to Consider
Alkermes currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Repligen Corporation (RGEN - Free Report) and Nabriva Therapeutics AG , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings estimates have been revised 15.1% upward for 2021 and 9.8% upward for 2022 over the past 60 days. The stock has increased 5% year to date.
Nabriva’s loss per share estimates have narrowed 45.8% for 2021 and 50.9% for 2022 over the past 60 days.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>